Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
- None.
- None.
Insights
The private placement financing secured by Tyra Biosciences is a substantial liquidity event, indicative of strong investor confidence. The involvement of institutional and accredited investors, especially RA Capital Management, is a testament to the potential they see in the company's pipeline. The pricing of the shares at $13.01, which aligns with at-the-market under Nasdaq rules, suggests a valuation agreement between the company and the investors, avoiding the discount often seen in private placements.
From a financial perspective, the immediate exercisability and lack of expiration of the pre-funded warrants are favorable terms for the investors, providing them with flexibility and reducing the risk of time decay on their investment. The gross proceeds of approximately $200 million will enhance Tyra Biosciences' balance sheet, allowing the company to accelerate its clinical programs and potentially increase its market value if successful outcomes are achieved.
The focus on developing precision medicines targeting FGFR biology has significant implications for the treatment of diseases such as achondroplasia, NMIBC and metastatic urothelial carcinoma. TYRA-300's status as an oral FGFR3-selective inhibitor positions it within a niche market, where a best-in-class agent could command substantial market share. The capital infusion will expedite the clinical development of TYRA-300 and TYRA-200, which could lead to breakthroughs in the treatment of these conditions.
Furthermore, the SNÅP platform represents a strategic asset in drug discovery, potentially leading to a diversified pipeline that could mitigate the risks associated with clinical trials and enhance the company's long-term prospects.
The biotechnology sector is highly competitive, with investor sentiment often swayed by clinical trial outcomes and regulatory milestones. Tyra Biosciences' successful financing round could signal market optimism regarding its strategic direction and product pipeline. The company's commitment to advancing its preclinical programs and leveraging its proprietary SNÅP platform for drug discovery may drive future growth.
It is important to monitor how these funds are allocated and managed, as efficient capital deployment is critical to achieving clinical milestones and delivering shareholder value. Additionally, the registration of securities with the SEC for resale could increase liquidity and attract a broader investor base, potentially stabilizing the stock price post-financing.
The financing was led by RA Capital Management, with participation by new and existing institutional investors, including Boxer Capital, BVF Partners, Nextech Invest Ltd (on behalf of one or more funds managed by it), OrbiMed, 5AM Ventures, a large investment management firm and a life-sciences focused institutional investor.
"We appreciate the support of RA Capital and our outstanding group of current and new investors as we further our mission of developing next-generation precision medicines that target FGFR biology," said Todd Harris, CEO of TYRA. "The additional funding strengthens our balance sheet at a time of strong momentum. We are focused on developing TYRA-300, an oral FGFR3-selective inhibitor, to become a best-in-class agent for achondroplasia, NMIBC and metastatic urothelial carcinoma, while advancing TYRA-200 and leveraging our SNÅP platform to discover new drug candidates."
In the PIPE, TYRA is selling an aggregate of approximately 15.4 million shares of its common stock (or pre-funded warrants in lieu thereof) at a price of
TYRA intends to use the net proceeds from the PIPE to advance the clinical development of TYRA-300 and TYRA-200, to advance its preclinical programs, and for drug discovery, working capital and general corporate purposes.
The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in
For more information about our science, pipeline and people, please visit https://tyra.bio/and engage with us on LinkedIn.
Forward Looking Statements
TYRA cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: statements related to: the timing, size and expectation of the closing of the PIPE; expectations regarding market conditions, the satisfaction of customary closing conditions related to the PIPE and the anticipated use of proceeds therefrom; and the potential to discover and develop next-generation precision medicines and develop a best-in-class agent. Such forward-looking statements involve substantial risks and uncertainties that could cause our actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by TYRA that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing; we are early in our development efforts and the approach we are taking to discover and develop drugs based on our SNÅP platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of commercial value; and other risks described in our prior press releases and filings with the SEC, including under the heading "Risk Factors" in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-inc-announces-200-million-private-placement-financing-302051976.html
SOURCE Tyra Biosciences
FAQ
What is the purpose of the private placement financing (PIPE) announced by Tyra Biosciences, Inc.?
Who led the private placement financing (PIPE) for Tyra Biosciences, Inc.?
How many shares of common stock is Tyra Biosciences, Inc. selling in the private placement financing (PIPE)?
What is the expected closing date for the private placement financing (PIPE) announced by Tyra Biosciences, Inc.?
What are the intended uses of the net proceeds from the private placement financing (PIPE) for Tyra Biosciences, Inc.?
